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OBJECTIVE—Type 1 diabetes results from selective T-cell–
mediated destruction of the insulin-producing -cells in the
pancreas. In this process, islet epitope–speciﬁc CD8
 T-cells play
a pivotal role. Thus, monitoring of multiple islet–speciﬁc CD8

T-cells may prove to be valuable for measuring disease activity,
progression, and intervention. Yet, conventional detection tech-
niques (ELISPOT and HLA tetramers) require many cells and are
relatively insensitive.
RESEARCH DESIGN AND METHODS—Here, we used a
combinatorial quantum dot major histocompatibility complex
multimer technique to simultaneously monitor the presence of
HLA-A2 restricted insulin B10–18, prepro-insulin (PPI)15–24, islet
antigen (IA)-2797–805, GAD65114–123, islet-speciﬁc glucose-6-phos-
phatase catalytic subunit–related protein (IGRP)265–273, and pre-
pro islet amyloid polypeptide (ppIAPP)5–13–speciﬁc CD8
 T-cells
in recent-onset diabetic patients, their siblings, healthy control
subjects, and islet cell transplantation recipients.
RESULTS—Using this kit, islet autoreactive CD8
 T-cells rec-
ognizing insulin B10–18, IA-2797–805, and IGRP265–273 were shown
to be frequently detectable in recent-onset diabetic patients but
rarely in healthy control subjects; PPI15–24 proved to be the most
sensitive epitope. Applying the “Diab-Q-kit” to samples of islet
cell transplantation recipients allowed detection of changes of
autoreactive T-cell frequencies against multiple islet cell–derived
epitopes that were associated with disease activity and corre-
lated with clinical outcome.
CONCLUSIONS—A kit was developed that allows simulta-
neous detection of CD8
 T-cells reactive to multiple HLA-A2–
restricted -cell epitopes requiring limited amounts of blood,
without a need for in vitro culture, that is applicable on stored
blood samples. Diabetes 59:1721–1730, 2010
T
ype 1 diabetes results from a selective T-cell–
mediated destruction of the insulin-producing
-cells in the pancreas. It is becoming increas-
ingly clear that islet epitope–speciﬁc CD8
 T-
cells play a pivotal role in the destruction process and
constitute a signiﬁcant portion of insulitis (1,2). In accor-
dance, nonobese diabetic mice lacking the expression of
major histocompatibility complex (MHC) class I are resis-
tant to autoimmune diabetes (3,4), whereas HLA-A2 trans-
genic nonobese diabetic mice develop accelerated disease
(5). Additionally, transfer of CD8
 T-cell clones resulted in
transfer of type 1 diabetes (6,7). Thus, detection and
monitoring of speciﬁc CD8
 T-cells may provide a valu-
able tool to assess the disease activity.
Islet cell transplantation has considerable potential as a
cure for type 1 diabetes (8). Several groups have reported
short-term success, using different islet isolation and im-
munosuppressive regimens (9–12), but long-term insulin
independence is rare (13). The rationale behind transplan-
tation of islet cells is replenishment of destructed cells.
Yet, as the insulin-producing cells were destructed by an
autoimmune response, islet cell transplantation could also
result in reactivation of the autoimmune response. Re-
cently, we have shown that proliferation of CD4
 T-cells
speciﬁc for GAD and IA-2 in patients who underwent islet
cell transplantation is associated with clinical outcome
(14). Yet, ultimately, the destruction of -cells is likely to
be caused by CD8 T-cells.
The epitopes recognized by the diabetes-speciﬁc human
autoreactive CD8
 T-cells are primarily derived from
-cell antigens, most importantly (pre-)(pro-)insulin. Pre-
viously, we showed that the presence of CD8
 T-cells
reactive to the naturally processed insulin–peptide B10–18
in HLA-A2 correlated with islet cell destruction (15).
Recently, another important epitope that was uncovered
as the signal peptide of pro-insulin was shown to contain
a glucose-regulated CD8
 T-cell epitope (prepro-insulin
[PPI]15–24) (16), but many other epitopes derived from
insulin and a range of other -cell–derived antigens, such
as GAD65 (17), islet antigen (IA)-2 (18), islet-speciﬁc
glucose-6-phosphatase catalytic subunit related protein
(IGRP) (19,20), and prepro islet amyloid polypeptide (ppI-
APP) (21), have been reported (rev. in 22). Ideally, moni-
toring for the presence of CD8
 T-cells reactive to all of
the above-mentioned epitopes simultaneously would be
desired, posing considerable constraints on blood volumes
accessible for monitoring of islet autoimmunity with con-
ventional immune assays.
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 T-cells reactive to -cell–
derived antigens requires staining of a large number of,
usually fresh, cells with HLA tetramers loaded with a
single peptide, or in vitro culture for functional immune
assays (proliferation, cytokine production [ELISPOT]).
Monitoring multiple epitope-speciﬁc CD8
 T-cell popula-
tions by conventional tetramer technology is generally
impossible because of the scarcity of material. Further-
more, detection of islet autoreactive T-cells is hampered
by their low precursor frequencies in circulation (23,24),
low T-cell receptor (TCR) avidity (15), potentially low
binding afﬁnity of peptide epitopes to HLA (25), a wide
range of candidate islet epitopes (22), and the existence of
regulatory T-cells (26,27).
Therefore, we used the recently described combinato-
rial quantum dot (Qdot) technique (28) to simultaneously
detect CD8
 T-cells speciﬁc for six different -cell–de-
rived antigens, a naturally occurring HLA-A2 derived pep-
tide, and a mix of viral epitopes in HLA-A2 multimers.
Using peripheral blood cells from recent-onset type 1
diabetic patients, their siblings, and control subjects, we
validated this technique and established the speciﬁcity of
these stainings. Subsequently, we monitored the presence
of reactive CD8
 T-cells before and at several time points
after clinical islet cell transplantation. Altogether, we
developed a high-throughput and relatively sensitive and
speciﬁc Diab-Q-kit, allowing simultaneous detection of
autoreactive CD8
 T-cells to multiple islet epitopes, which
is applicable to small volumes of stored blood samples to
allow screening in multicenter immune intervention trials.
RESEARCH DESIGN AND METHODS
Recent-onset diabetic patients. Samples from recent-onset type 1 diabetic
patients were retrieved from the Kolibri type 1 diabetes cohort, which
includes material from 350 patients with juvenile-onset type 1 diabetes
(median age 8.7 years [range 1–17 years]). The cohort was collected consec-
utively after diagnosis by pediatricians in the southwestern part of the
Netherlands between 1995 and 1999. The diagnosis was made according to
International Society of Pediatric and Adolescent Diabetes and World Health
Organization criteria. All patients were HLA-A2 positive. Peripheral blood
mononuclear cells (PBMCs) were isolated by Ficoll-Isopaque density gradient
centrifugation. PBMCs were frozen in a solution of 20% human pooled serum
and 10% DMSO (5–10  10
6 cells per vial) and kept in liquid nitrogen until use.
Blood samples of islet transplant recipients were stored in liquid nitrogen for
12–36 months.
Islet cell transplanted patients. Seven patients were transplanted with islet
cell grafts after signing informed consent and under appropriate ethical
approval as reported previously (29). None of the patients presented alloan-
tibodies against HLA alloantigen that was expressed on the donor cells before
transplantation. Graft recipients were long-term type 1 diabetic patients
without any earlier transplantation, with plasma C-peptide 0.09 ng/ml, large
variation in blood glucose levels (coefﬁcient of variation 25%), A1C concen-
tration 7%, and one or more chronic diabetes lesions. Exclusion criteria
were body weight 90 kg, active smoking, pregnancy, disturbed liver function
tests, history of hepatic disease, presence of HLA antibodies, or negative
Epstein-Barr virus serostatus.
Donor organs were procured from multiple heart-beating donors through
the Eurotransplant Foundation (Leiden, the Netherlands) and processed at
the Beta Cell Bank in Brussels, Belgium, to -cell–enriched fractions that
were cultured for 2–20 days (median 6 days). Immunosuppressive induction
therapy consisted of antithymocyte globulin (ATG) (Fresenius HemoCare,
Redmond, WA) with a single infusion of 9 mg/kg and subsequently with 3
mg/kg for 6 days except when the T-cell count was 50/mm
3. Maintenance
immunosuppression consisted of tacrolimus (Prograft; Fujisawa/Pharma Lo-
gistics; dose according to trough level: 8–10 ng/ml in the ﬁrst 3 months
post-transplantation, 6–8 ng/ml thereafter) and mycophenolate mofetil (2,000
mg/day; Roche, Basel, Switzerland). The HLA typing of the patients is depicted
in the supplementary table (available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1486/DC1). Islet cell recipients were
age-matched with the healthy control subjects.
Qdot-labeled HLA-A2–peptide multimers. Multimeric HLA-A2–peptide
complexes were prepared essentially as previously described (30). Brieﬂy,
recombinant HLA-A2 and human 2-macroglobulin were solubilized in urea
and injected together with each synthetic peptide into a refolding buffer
consisting of 100 mmol/l Tris (pH 8.0), 400 mmol/l arginine, 2 mmol/l EDTA, 5
mmol/l reduced glutathione, and 0.5 mmol/l oxidized glutathione. Refolded
complexes were biotinylated by incubation for2ha t30°C with BirA enzyme
(Avidity, Denver, CO). The biotinylated complexes were puriﬁed by gel
ﬁltration on a Superdex 75 column (Amersham Pharmacia Biotech, Piscat-
away, NJ). Multimeric HLA–peptide complexes were produced by addition of
streptavidin-conjugated Qdots (28) (Invitrogen, Breda, the Netherlands) to
achieve a 1:20 streptavidin-Qdot/biotinylated HLA class I ratio. Qdots used are
Qdot-585, -605, -655, -705, and -800. Samples from HLA-A2–positive subjects
were stained with a mixture containing six diabetes-associated epitopes, a
HLA-A2 epitope expressed in HLA-A2, and a mix of viral antigens (Table 1).
Cell staining with Qdot-labeled multimeric complexes. PBMCs (2  10
6)
were stained simultaneously with all Qdot-labeled multimers (0.1 g of each
speciﬁc multimer) in 60 l of PBS supplemented with 2% BSA and incubated
for 15 min at 37°C (Table 1). Subsequently, 10 l antigen-presenting cell
(APC)-labeled anti-CD8 (stock 1:10) and 10 l ﬂuorescein isothiocyanate–
labeled anti-CD4, -CD14, -CD16, -CD19, and -CD40 antibodies (Becton Dick-
inson, Franklin Lakes, NJ) were added for 30 min at 4°C. After being washed
twice, cells were resuspended in PBS/2% BSA containing 7-aminoactinomycin
D (7-AAD; eBioscience, San Diego, CA) to exclude dead cells, and samples
were analyzed using the LSR II (Becton Dickinson).
Statistical analysis. Statistical analysis on recent-onset diabetic patients
versus their siblings was performed using a Wilcoxon matched-pairs test.
Differences between recent-onset diabetic patients and control subjects were
tested using the unpaired t test with Welch correction (for HLA-A2 peptide
and PPI15–24; passed normality test) or the Mann-Whitney test (all other
epitopes). Changes in epitope reactivity of islet cell transplant recipients over
time were tested using the Friedman test followed by a Dunn multiple
comparisons test. All statistical analyses were performed using GraphPad
Prism software.
RESULTS
Simultaneous monitoring of multiple epitopes.
Recently, the use of multidimensional encoded MHC mul-
timers was reported as a powerful tool to allow the
parallel detection of multiple antigen-speciﬁc T-cell popu-
lations within a single sample (28). This technology opens
the possibility of designing kits of deﬁned peptide-MHC
multimers that may be used to report on disease state or
vaccine response. To test this concept, a Qdot-based
combinatorial approach was developed to simultaneously
monitor multiple islet epitopes associated with the devel-
opment of type 1 diabetes. HLA-A2 molecules were loaded
with identiﬁed diabetes peptides, and MHC multimers
were created by labeling with Qdots such that T-cells
speciﬁc for each of these epitopes are deﬁned by binding
of MHC multimers with a unique combination of two
Qdots (Table 1).
During ﬂow cytometric analysis, single-cell lymphocytes
were gated that stained positive for CD8 (on average
TABLE 1
Combinations of Qdot-labeled HLA-A2 multimers
Origin Position/protein Sequence Signal
CMV pp65 NLVPMVATV Qdot 585  655
EBV LMP2 CLGGLLTMV Qdot 585  655
Measles H250 SMYRVFEVGV Qdot 585  655
HLA-A2 140–149 YAYDGKDYIA Qdot 585  605
Insulin B 10–18 HLVEALYLV Qdot 605  655
PPI 15–24 ALWGPDPAAA Qdot 705  655
GAD65 114–123 VMNiLLQYVV Qdot 800  655
IA-2 797–805 MVWESGCTV Qdot 705  605
IGRP 265–273 VLFGLGFAI Qdot 800  605
ppIAPP 5–13 KLQVFLIVL Qdot 705  800
CVM, cytomegalovirus; EBV, Epstein-Barr virus.
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negative for the “dump”-channel (combination of CD4,
CD14, CD16, CD19, and CD40) and negative for the
exclusion (viability) dye 7-AAD (Fig. 1A). Staining of
PBMCs of healthy control subjects (Fig. 1B, typical exam-
ple shown) with a mixture of three virus-derived epitopes
resulted in a clearly distinguishable population character-
ized by a positive signal for both ﬂuorescent signals used
to encode the peptide-MHC multimers. A clear population
of CD8
 T-cells reactive to insulin B10–18 was seen in the
sample of the recent-onset diabetic patient. These insulin
B10–18-reactive CD8 T-cells were also found in an islet cell
transplantation recipient, in which virus-speciﬁc CD8

T-cells also were seen. No CD8
 T-cells reactive to insulin
B10–18 were found in the healthy control subjects (Fig. 1),
whereas few virus-speciﬁc CD8
 T-cells were detectable
in samples of recent-onset diabetic patients (Fig. 1). In
terms of reproducibility, the coefﬁcient of variation be-
tween experiments was 9.5% across Qdot multimers. For
the separate epitopes, the variation varied (HLA-A2 pep-
tide, 10.8%; virus mix, 34.9%; InsB, 15.9%; IA-2, 0.0%; IGRP,
0.0%; PPI, 6.3%; GAD65, 4.5%; and ppIAPP, 6.9%) (supple-
mentary Figs. 1–3, available in the online appendix).
Selectivity of the examined epitopes. To determine
whether the simultaneously measured islet epitopes were
sensitively and speciﬁcally detected in the circulation of
recent-onset type 1 diabetic patients, we determined the
frequency of CD8
 T-cells speciﬁc for all currently known
epitopes in recent-onset diabetic patients, their siblings
(when available), and healthy control subjects.
Unfortunately, of the 20 recent-onset diabetic patients
studied, material from just 5 HLA-A2–expressing siblings
was available, corresponding to 3 recent-onset diabetic
patients, allowing a direct comparison of the presence of
CD8
 T-cells speciﬁc for the islet epitopes (Fig. 2, left
panels). Generally, the frequency of -cell antigen-reactive
CD8
 T-cells was higher in recent-onset diabetic patients
than in their siblings, but because of low numbers, no
statistically signiﬁcant differences were observed. Also,
we analyzed the frequency of CD8
 T-cells in the circula-
tion of all examined recent-onset diabetic patients (n 
20) and matched control blood donors (n  15). Clearly,
the frequencies of CD8
 T-cells recognizing the islet
cell–derived epitopes were all signiﬁcantly higher in re-
cent-onset diabetic patients than in control subjects. Con-
versely, a higher frequency of virus-reactive CD8
 T-cells
was seen in the control subjects. These data point to
higher frequencies of islet-reactive CD8
 T-cells within the
circulation of recent-onset diabetic patients.
Next, we determined the sensitivity and speciﬁcity of
T-cell responses to each epitope, deﬁning a frequency of
one cell reactive in 10,000 CD8
 T-cells (i.e., 0.010%) as a
cutoff, with the exception of the IGRP265–273, where a
frequency of 1 in 20,000 (i.e., 0.005%) was used as a cutoff.
Three epitopes were found to be 100% speciﬁc because no
relevant frequencies were seen in the control subjects:
FIG. 1. Flow cytometric analysis of epitope-speciﬁc CD8
 T-cells using the combinatorial Qdot approach. A: Gating strategy: viable CD8
 single
T-cells were analyzed by gating lymphocytes on the basis of FSC-A and SSC-A. Subsequently, single cells were gated (FSC-W and FSC-H) and
CD8-APC–positive but dump-channel ﬂuorescein isothiocyanate (CD4  CD14  CD16  CD20  CD40)–negative cells were gated, of which the
7-AAD–positive cells were gated out. B: Qdot staining: within the viable CD8
 single T-cells, the cells recognizing the epitopes in the viral mix
(Qdot 585  655) and insulin B10–18 (Qdot 605  655) are shown as a typical example for a healthy control, a recent-onset type 1 diabetic patient
(T1D), and a pretransplantation islet cell recipient.
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most speciﬁc and considerably sensitive epitope detected;
IA-2797–805 and IGRP265–273 provided a speciﬁcity of 100%
but a sensitivity of 25% (Table 2). The epitope with the
highest sensitivity was PPI15–24, as epitope-speciﬁc CD8

T-cell reactivity was detectable in 17 of 20 recent-onset
diabetic patients (85%). Yet, 4 of 15 control subjects also
exhibit CD8
 T-cells against this epitope, affecting the
speciﬁcity (73%). Qdot stainings of HLA-A2–negative pa-
tients or control subjects with HLA-A2 multimers were
always below the detection limit (n  27), regardless of
the peptide epitopes tested, supporting the speciﬁcity of
these reagents. Overall, our data indicate that we can
discretely monitor the speciﬁc presence of multiple
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0.04
0.2
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0.01 1.00
InsB10-18
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0.05
0.06
<0.0001 0.31
PPI15-24
RO Sibs RO Con
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0.01
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0.03
0.04
0.05
0.002 0.06
IA-2797-805
RO Sibs RO Con
0.00
0.02
0.04
0.06
0.08
0.02 0.06
GAD65114-123
RO Sibs RO Con
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.0002 0.06
IGRP265-273
RO Sibs RO Con
0.000
0.005
0.010
0.015
0.020
0.0006 0.90
ppIAPP5-13
RO Sibs RO Con
0.00
0.01
0.02
0.03
0.002 0.06
FIG. 2. Frequencies of epitope-speciﬁc CD8
 T-cells in recent-onset diabetic patients, their siblings, and healthy control subjects. The
frequencies of CD8
 T-cells recognizing the epitopes HLA-A2140–149, the viral mix, insulin B10–18, PPI15–24, GAD65114–123, IA-2797–805, IGRP265–273,
and ppIAPP5–13 in HLA-A2 as determined by ﬂow cytometry are depicted. First, the frequency detected in recent-onset diabetic patient material
(RO, n  3) and that of their siblings (Sibs, n  5) was compared (left panels). Statistical analysis was performed using the Wilcoxon
matched-pairs test. The frequencies detected in all RO (n  20) and control subjects (Con, n  15) were compared (right panels). Statistical
analysis was performed using the unpaired t test with Welch correction (for HLA-A2 peptide and PPI15–24) or the Mann-Whitney test (all other
epitopes).
TABLE 2
Selectivity of the epitopes tested
Epitope Cutoff
Control
subjects
Recent-onset
type 1
diabetic
patients Sensitivity Speciﬁcity
n 15 20
Insulin B10–18 1 in 10,000 0 13 65 100
Pre-pro-insulin15–24 1 in 10,000 4 17 85 73
IA-2797–805 1 in 10,000 0 5 25 100
GAD65114–123 1 in 10,000 1 5 25 93
IGRP265–273 1 in 20,000 0 5 25 100
ppIAPP5–13 1 in 10,000 2 8 40 87
Data are n or percent for sensitivity and speciﬁcity.
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 T-cells simultaneously using the
newly developed Diab-Q-kit.
Epitope-speciﬁc CD8
 T-cells in islet cell transplan-
tation. Next, the Diab-Q-kit was used to monitor the
presence of HLA-A2 epitope-speciﬁc CD8
 T-cells in seven
islet cell transplant recipients, at four different time points:
before transplantation, 6 weeks thereafter (reconstitution
of the T-cell compartment after ATG-induction treatment),
26 weeks after transplantation, and 52 weeks after trans-
plantation. Examination of the frequency of CD8
 T-cells
recognizing endogenously processed HLA-A2 peptide pre-
sented in the HLA-A2 molecule showed reactivity in two
recipients at two different time points (Fig. 3). Viral
reactivity was seen in two of seven HLA-A2–positive islet
cell transplantation recipients before transplantation (Fig.
3, viral mix), but clearly the induction therapy with ATG
strongly reduced their frequency in circulation. One year
after transplantation, virus-speciﬁc T-cells had reap-
peared, albeit to a lower level than before transplantation.
Despite disease durations up to several decades, islet
autoreactive CD8
 T-cells were still detectable in the
majority of type 1 diabetic patients at the time of islet
transplantation (0 weeks; Fig. 4). No particular islet
epitope or pattern of reactivity dominated. After reconsti-
tution of the T-cell compartment under maintenance im-
munosuppression after ATG induction therapy (4 weeks;
Fig. 4), the cumulative numbers of autoreactive CD8

T-cells waned in a minority of recipients. In four of seven
patients, islet autoreactivity increased after islet transplan-
tation, one patient displayed stable frequencies of circu-
lating islet reactive T-cells, and, in two case subjects, a
stable declined was observed.
The dynamics of T-cells speciﬁc for the (pre-)(pro-)
insulin epitopes (insulin B10–18 and PPI15–24) were most
pronounced (Fig. 3): considerable frequencies of these
cells were detected before islet cell infusion and (re-)
emerged at later time points thereafter. In contrast, T-cell
frequencies against GAD65114–123 and IGRP265–273 were
infrequently seen, with only a single increase late after
islet implantation in patients 6 and 7, respectively (Fig. 3).
These two case subjects also displayed the most epitope
spreading at that time point (Fig. 4). Of note, patient ct #7
cytomegalovirus-converted after transplantation.
Clinical outcome. Subsequently, the patterns of autore-
active CD8
 T-cell frequencies were correlated with clin-
ical outcome. All immune parameters were deﬁned and
interpreted without prior knowledge of clinical outcome.
Because reactivity to single epitopes was sometimes ob-
served in healthy control subjects (Fig. 2), only the pres-
ence of two or more epitope-speciﬁc autoreactive CD8

T-cells at any time after transplantation was interpreted as
being detrimental; to predict the clinical outcome based
on the full autoimmune spectrum, the presence of CD8

T-cells reactive to the recently uncovered PPI epitopes
PPI76–84 and PPI79–88 in HLA-A3 as well as PPI4–13 in
HLA-B7 were also considered (W.W.U., J.H.V. et al., un-
published observations) as indicated in Table 3. Conse-
quently, the data obtained with the novel Diab-Q-kit
predicted that six of seven recipients studied would not
reach insulin independence.
Previously, we reported that proliferation of CD4
 T-
cells to whole IA-2 and GAD65 before transplantation
predicted transplantation outcome (14). For comparison,
the prediction of clinical outcome based on this prolifer-
ation assay was also taken into consideration (Table 3).
Prediction based on proliferation of islet-speciﬁc CD4
T-cells pointed toward four patients not reaching insulin
independence. For three patients, there was agreement in
the prediction by both immunological end points.
The Diab-Q-kit predicted that six recipients would re-
main insulin requiring, of which four actually required
exogenous insulin injection. Thus, this method showed a
prediction accuracy of 66%. The prediction of clinical
outcome based on proliferation (14) predicted insulin
requirement in four case subjects, of which three were
correct (accuracy of 75%). However, when both methods
agreed in their prediction, all transplant recipients re-
mained insulin requiring after transplantation, and thus
the combined method provided an accuracy of 100%,
underlining the importance of monitoring CD8
 T-cell
frequencies.
DISCUSSION
Our study is the ﬁrst to implement simultaneous detection
of multiple islet cell–speciﬁc CD8
 T-cell responses, by
development of the Diab-Q-kit. To this purpose, multidi-
mensional encoded MHC multimers were used. Recently,
their use was extensively validated and shown to be a
powerful tool to parallel detect antigen-speciﬁc T-cells
(28). Here, we determined the sensitivity and speciﬁcity of
previously reported HLA-A2 restricted epitopes (15–18,20)
in recent-onset type 1 diabetic patients, their siblings,
control blood donors, and islet cell transplant recipients.
Insulin B10–18 was found to be 100% speciﬁc, as no CD8

T-cell frequencies of 1 in 10,000 cells were seen in
PBMCs from healthy control subjects. Although this also
holds true for IGRP265–273 and IA-2797–805, CD8
 T-cells
recognizing insulin B10–18 showed the highest sensitivity of
these epitopes. The relevance of insulin B10–18 in type 1
diabetes is underlined by previously published observa-
tions that PBMCs from a type 1 diabetic patient produced
interferon- in response to this peptide (31), that expres-
sion of insulin B10–18 renders target cells sensitive to
killing by CTL lines (32), and, most importantly, that the
presence of insulin B10–18-speciﬁc CD8
 T-cells correlates
with destruction of -cells (15). As the transplantation of
isolated islet cells can result in reactivation of CD8

T-cell–mediated autoreactivity toward islet cell–speciﬁc
epitopes, peripheral blood from islet cell transplantation
recipients can be used to monitor the factors important in
-cell destruction. Also in this cohort, the presence of
insulin B10–18-reactive CD8
 T-cells after transplantation
correlated with a poor clinical outcome, with the excep-
tion of the cytomegalovirus-converted recipient.
Recently, we reported PPI15–24 as a naturally produced
and presented HLA-A2 epitope (16). Cytotoxic CD8
 T-
cells against this peptide could be cloned that killed -cells
in vitro in a glucose concentration–dependent fashion,
linking -cell immunogenicity with its functional activity
(16). This study underscores the relevance of CD8 islet
autoreactivity in the pathogenesis of type 1 diabetes, and it
indicates that -cells are actively involved in their own
demise. Interestingly, this PPI epitope provided the high-
est sensitivity (85%) combined with a speciﬁcity of 73%. All
but one HLA-A2–positive islet cell recipient exhibited
increased frequencies against PPI15–24 at a time point after
transplantation. Of these patients, half did not reach
insulin independence after transplantation.
The HLA-A2–restricted islet epitopes IA-2797–805,
GAD65114–123, IGRP265–273, and ppIAPP5–13 also exhibited a
highly speciﬁc staining, with only incidental reactivity in
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ported results (18), we did not observe any CD8
 T-cells
reactive to IA-2797–805 in healthy control subjects. How-
ever, we performed a direct assessment of the CD8
 T-cell
frequency in PBMCs, rather than functional assays,
whereas Takahashi et al. (18) cultured CD8
 cells for 14
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FIG. 3. Frequencies of epitope-speciﬁc CD8
 T-cells in islet cell recipients over time. The frequencies of CD8
 T-cells recognizing the epitopes
HLA-A2140–149, the viral mix, insulinB10–18, PPI15–24, GAD65114–123, IA-2797–805, IGRP265–273, and ppIAPP5–13 in HLA-A2 as determined by ﬂow
cytometry are depicted. The frequencies of CD8
 T-cells were measured at four different time points: before transplantation, 6 weeks thereafter
(reconstitution of the T-cell compartment after ATG induction treatment), 26 weeks after transplantation, and 52 weeks after transplantation.
Changes in epitope reactivity of islet cell transplant recipients over time were tested using the Friedman test followed by a Dunn multiple
comparisons test with *P < 0.05 values considered statistically signiﬁcant. Data points of recent-onset diabetic patients are depicted to allow
easy comparison of “recent-onset reactivity” and “islet cell transplant reactivity.”
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a cocktail of cytokines. Their observations may therefore
be inﬂuenced by in vitro phenomena.
Reactivity to IA-2797–805, GAD65114–123, and IGRP265–273
were almost exclusively seen in combination with reactiv-
ities to insulin B10–18 and/or PPI15–24, suggesting that PPI
epitopes may comprise the primary epitopes after reacti-
vation of autoimmunity upon islet cell transplantation,
whereas reactivity to the other may result from epitope
spreading.
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FIG. 4. Cumulative frequencies of epitope-speciﬁc CD8
 T-cells in islet cell recipients at different time points. The cumulative frequencies of
CD8
 T-cells recognizing the epitopes insulin B10–18, PPI15–24, GAD65114–123, IA-2797–805, IGRP265–273, and ppIAPP5–13 in HLA-A2 as determined by
ﬂow cytometry are depicted for each islet cell recipient individually. Note the different axis for patients ct #6 and ct #7.
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tive CD8
 T-cells after the transplantation induction ther-
apy (i.e., at 6 weeks), CD8
 T-cells speciﬁc for insulin
B10–18 and PPI15–24 were among the ﬁrst CD8
 T-cells to
occur. Their occurrence after ATG treatment may have
resulted from homeostatic proliferation (33–35), indicat-
TABLE 3
Clinical outcome
Patient
No.
CD8 T-cell reactivity against islet epitopes
after transplantation
Prediction
Clinical outcome# CD8 CD4
0 weeks 6 weeks 26 weeks 52 weeks Diab-Q-kit Proliferation Insulin needs CV (%)
Time to
Ins Indep
ct #1 Tx1
A2 A3 B7
Tx2
A2 A3
Ins Req Ins Req 26.5 NA HLA-A2 ppIAPP
HLA-A3 PPI76–84* PPI76–84* PPI76–84*
PPI79–88* PPI79–88* PPI79–88*
HLA-B7 PPI4–13* PPI4–13*
ct #2 Tx1
B7
Ins Req Ins Req Ins Req 20.0 NA HLA-A2 PPI
GAD65
HLA-B7 PPI4–13* PPI4–13*
ct #3 Tx1
A2
Tx2
A2
Ins Req Ins Req Ins Req 50.2 NA HLA-A2 B10–18 B10–18
PPI PPI PPI PPI
GAD65 GAD65
ppIAPP ppIAPP
ct #4 Tx1
A2
Tx2
A2 Ins Req Ins Indep 32.1 19.6
weeks HLA-A2 B10–18
PPI
ct #5 Tx1
A2 A3
Tx2
A2
Ins Req Ins Indep 22.2 15.0
weeks HLA-A2 PPI PPI
HLA-A3
HLA-B7 PPI4–13*
ct #6 Tx1 Tx2
A2
Ins Req Ins Req Ins Req 24.1 NA
HLA-A2 B10–18 B10–18
PPI PPI
IA-2
GAD65
ppIAPP ppIAPP ppIAPP
ct #7† Tx1
A2
Tx2
A2
Ins Req Ins Indep 25.4 26.9
weeks
HLA-A2 B10–18 B10–18 B10–18
PPI PPI PPI
IA-2 IA-2
IGRP
ppIAPP
Overview of all detected CD8-reactive epitopes at four different time points. For each recipient, the ﬁrst and second (if applicable) transplantation
is listed including the presence of the relevant HLA restriction in the graft received. In the resulting prediction of clinical outcome, the presence
of CD8 T-cells against novel HLA-A3– and HLA-B7–restricted epitopes also was considered. Clinical outcome is deﬁned as insulin independence
(Ins Indep) or still requiring insulin (Ins Req), the coefﬁcient of variation in fasting glycemia in the ﬁrst 6 months (CV), and the time to reach insulin
independence. NA, not applicable. #All experiments were performed blinded from clinical outcome. *Non-HLA-A2–restricted T-cell responses
(W.W.U., J.H.V. et al., unpublished observations). †This patient cytomegalovirus-converted upon transplantation.
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 T-cells, although undetectable in the
peripheral blood after ATG induction, remain as a
memory population in lymphatic organs. Because in one
of these patients these cells were undetectable because
transplantation, this may indicate that these cells persist
many years after destruction of the islet cells. From
these data, we speculate that homeostatic proliferation
of autoreactive T-cells, including CD8-expressing cells,
may be detrimental to islet cell transplantation, similar
as homeostatic proliferation of alloreactive cells can be
to solid organ transplantation (36,37). We cannot con-
clude on any order of reactivity among islet autoanti-
gens, because there may be technical explanations for
differences in precursor frequencies of the correspond-
ing islet autoreactive CD8 T-cells, such as avidity of the
Qdots for the TCR or afﬁnity of the peptide epitope to
HLA-A2, that contribute to differences in the detection
limit.
Virus-speciﬁc CD8 T-cells showed frequencies in some
control subjects that were higher than those in recent-
onset diabetic subjects, an inverse pattern compared with
frequencies of autoreactive T-cells in patient and healthy
subjects. Yet, the difference was moderate and was lost
completely if frequencies of virus-speciﬁc T-cells of pa-
tients before islet transplantation were combined with
those of patients with newly diagnosed diabetes. We have
no clear explanation for this trend, other than patients
being slightly younger than control subjects. Yet, this
ﬁnding suggests that the increases in antigen-speciﬁc CD8
T-cells in type 1 diabetes are not a general phenomenon
reﬂecting hyperimmune reactivity per se but seem more
speciﬁc for islet autoreactive T-cells.
Even though the gate settings will be largely similar
among individuals and among experiments, analyzing
(auto)antigen T-cell speciﬁcities is subject to subtle differ-
ences in background stainings between individual subjects
that require adjusting the gate settings accordingly. This
may partly result from the need to compensate the light
channels on each day that blood samples are analyzed on
the FACS LSR II. Importantly, the minor differences in
background staining did not distinguish patients from
healthy subjects. We recommend that a longitudinal series
of blood samples from a given subject be analyzed on the
same day to minimize interassay variation, as we pursued
for the analyses of blood samples of islet transplant
recipients. We contend that the availability of a second
dimension of staining in our combinatorial approach (each
epitope being represented by two different colors) facili-
tates setting the gates and to a great extent copes with the
difﬁculties of distinguishing background from positive
staining of low-avidity TCR.
It will be interesting to use our new technology to assess
functional and phenotypic differences in islet autoreactive
T-cells between type 1 diabetic patients and other subjects
(siblings, healthy unrelated subjects, and patients with
other diseases). Preliminary results suggest that CD8
T-cells recognizing the PPI15–24 epitope in an islet cell–
transplanted patient are largely of a memory phenotype
(supplementary Fig. 2).
In conclusion, our novel, highly sensitive detection
system allows for direct assessment of circulating autore-
active CD8
 T-cells against an array of islet epitopes
simultaneously. Another major advance over the current
procedures to determine islet-speciﬁc epitopes is the
freedom from in vitro culture and expansion that is
otherwise required in most studies on novel diabetes-
associated antigens to be able to detect responses (15–18).
Testing multiple epitope speciﬁcities in the same sample
further reduces the blood volumes required for analysis
and extends opportunities for testing for additional and
novel immune reactivities. Finally, our methods provided
applicable and informative data on thawed blood samples
that had been stored for up to 15 years, for the ﬁrst time
allowing assessment of cellular islet autoreactivity retro-
spectively, and enabling use in the context of large cohorts
and multicenter immune intervention studies. It is con-
ceivable that other or yet to be discovered epitopes may
provide a stronger correlation with clinical outcome. Even
though the currently used Qdot-MHC multimer technique
allows a highly sensitive, combinatorial assessment of
multiple islet epitope-speciﬁc CD8
 T-cell populations in
type 1 diabetes to study pathogenesis, prediction, progres-
sion, and intervention of the disease, it can be modiﬁed
and extended to up to 25 different epitopes in the future.
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